Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It… Read more
Ryvu Therapeutics SA - Asset Resilience Ratio
Ryvu Therapeutics SA (RVU) has an Asset Resilience Ratio of 18.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Ryvu Therapeutics SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Ryvu Therapeutics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł47.43 Million | 18.58% |
| Total Liquid Assets | zł47.43 Million | 18.58% |
Asset Resilience Insights
- Good Liquidity Position: Ryvu Therapeutics SA maintains a healthy 18.58% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Ryvu Therapeutics SA Industry Peers by Asset Resilience Ratio
Compare Ryvu Therapeutics SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Ryvu Therapeutics SA (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Ryvu Therapeutics SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.39% | zł65.86 Million | zł378.78 Million | -26.20pp |
| 2023-12-31 | 43.58% | zł175.73 Million | zł403.20 Million | +43.47pp |
| 2022-12-31 | 0.11% | zł528.00K | zł474.98 Million | -2.07pp |
| 2021-12-31 | 2.18% | zł4.99 Million | zł228.81 Million | -6.26pp |
| 2020-12-31 | 8.45% | zł24.97 Million | zł295.64 Million | +8.52pp |
| 2018-12-31 | -0.08% | zł-196.04K | zł255.70 Million | +0.11pp |
| 2017-12-31 | -0.19% | zł-196.04K | zł103.57 Million | -0.64pp |
| 2014-12-31 | 0.45% | zł120.00K | zł26.80 Million | -0.22pp |
| 2013-12-31 | 0.67% | zł120.00K | zł17.98 Million | +1.72pp |
| 2012-12-31 | -1.06% | zł-162.04K | zł15.35 Million | -0.50pp |
| 2011-12-31 | -0.56% | zł-98.08K | zł17.50 Million | -- |